| 5 | 1/1 | 返回列表 |
| 查看: 2292 | 回復(fù): 11 | |||||
| 當(dāng)前只顯示滿足指定條件的回帖,點(diǎn)擊這里查看本話題的所有回帖 | |||||
[交流]
GSK被調(diào)查,會(huì)對(duì)醫(yī)藥行業(yè)各個(gè)產(chǎn)業(yè)鏈產(chǎn)生什么影響 已有11人參與
|
|||||
| 大家都來深入淺出的分析一下 |
新藥研發(fā)必備資料 | 行業(yè)動(dòng)態(tài) |
金蟲 (小有名氣)
銀蟲 (小有名氣)
|
柳葉刀文章,轉(zhuǎn)自丁香園,分析GSK事件,說中國(guó)醫(yī)患問題可能與醫(yī)生和某些藥企的不健康關(guān)系有關(guān),請(qǐng)看下文: Doctors and pharma in China The Lancet Doctor—patient relationships in China are in crisis. Doctors have been injured or even killed by patients at work. One of the major drivers might be the unhealthy and unethical relations between many doctors and some drug companies. On July 8, GlaxoSmithKline (GSK) said that they were investigating allegations that its staff had improperly used cash and other incentives to encourage the prescription of onabotulinumtoxin A (Botox) in China. The company added that “inquiries to date have found no evidence of bribery or corruption in relation to our sales and marketing of therapeutic Botox in China.” The Lancet has no evidence to suggest that the allegations against GSK in China are true. However, some observers claim that bribing doctors to boost drug prescriptions by some drug companies is an open secret, and that this alleged practice has compromised the public's trust in doctors. The varieties of unethical relationships that exist between some doctors and some of the drug companies in China are said to range from cash kickbacks, lavish gifts or entertainment, ghost writing services, sponsored supplements in journals, and all-expenses-paid trips. There is real concern that doctors' prescriptions are therefore not based solely on patient need and clinical evidence, but may be biased by commercial interests. The perceived unethical association between physicians and industry in China is worrying, because it inevitably harms patients as well as doctors. It damages the doctor—patient relationship and, ultimately, China's whole health system. The GSK China allegations, although unproven, have clearly rung an alarm bell for China's regulatory authorities to ensure the drug industry promotes products in a responsible, ethical, and professional way. Chinese doctors should rely on evidence-based clinical guidelines to inform their practice, and are in urgent need of guidance on their collaborations with the drug industry in various areas such as patient care, professional education, and research. Furthermore, training for doctors in China on managing their relationships ethically with the drug industry and other organisations should start at medical school and be part of continuing professional education. |
銀蟲 (正式寫手)
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求調(diào)劑一志愿武漢理工大學(xué)材料工程(085601) +3 | WW.' 2026-03-23 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 招08考數(shù)學(xué) +6 | laoshidan 2026-03-20 | 14/700 |
|
|
[考研] 284求調(diào)劑 +6 | Zhao anqi 2026-03-22 | 6/300 |
|
|
[考研] 一志愿華中農(nóng)業(yè)071010,總分320求調(diào)劑 +5 | 困困困困坤坤 2026-03-20 | 6/300 |
|
|
[考博] 招收博士1-2人 +3 | QGZDSYS 2026-03-18 | 4/200 |
|
|
[考研] 求助 +5 | 夢(mèng)里的無言 2026-03-21 | 6/300 |
|
|
[考研] 307求調(diào)劑 +3 | 余意卿 2026-03-18 | 3/150 |
|
|
[考研] 299求調(diào)劑 +5 | shxchem 2026-03-20 | 7/350 |
|
|
[考研] 一志愿華南師大 070300(化學(xué))304分求調(diào)劑 +3 | 0703武芊慧雪304 2026-03-18 | 3/150 |
|
|
[考研] 材料專碩英一數(shù)二306 +7 | z1z2z3879 2026-03-18 | 7/350 |
|
|
[考研] 一志愿中海洋材料工程專碩330分求調(diào)劑 +8 | 小材化本科 2026-03-18 | 8/400 |
|
|
[考研] 330求調(diào)劑 +4 | 小材化本科 2026-03-18 | 4/200 |
|
|
[考研] 329求調(diào)劑 +9 | 想上學(xué)吖吖 2026-03-19 | 9/450 |
|
|
[考研] 材料學(xué)求調(diào)劑 +4 | Stella_Yao 2026-03-20 | 4/200 |
|
|
[考研] 261求B區(qū)調(diào)劑,科研經(jīng)歷豐富 +3 | 牛奶很忙 2026-03-20 | 4/200 |
|
|
[考研] 085410人工智能專碩317求調(diào)劑(0854都可以) +4 | xbxudjdn 2026-03-18 | 4/200 |
|
|
[考研] 一志愿中國(guó)海洋大學(xué),生物學(xué),301分,求調(diào)劑 +5 | 1孫悟空 2026-03-17 | 6/300 |
|
|
[考研] 085600材料與化工調(diào)劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|
|
[考研] 0703化學(xué)調(diào)劑 +5 | pupcoco 2026-03-17 | 8/400 |
|
|
[考研] 材料工程專碩調(diào)劑 +5 | 204818@lcx 2026-03-17 | 6/300 |
|